Structure via PubChem · Public domain (PubChem)
coluracetam
Sign in to saveColuracetam (INN; development code BCI-540; formerly MKC-231) is a purported nootropic agent of the racetam family. It contains a chemical group that is a bioisostere of the 9-amino-tetrahydroacridine family. It was initially developed and tested by the Mitsubishi Tanabe Pharma Corporation for Alzheimer's disease. After the drug failed to reach endpoints in its clinical trials it was in-licensed by BrainCells Inc for investigations into major depressive disorder (MDD), which was preceded by being awarded a "Qualifying Therapeutic Discovery Program Grant" by the state of California. Findings fr
In the Vinony graph
Vinony's link graph records 285 inbound references to coluracetam, and connects out to botulinum toxin group, chlorpyrifos and metrifonate.
It sits within the topics Acetamides, Chemical pages without DrugBank identifier and Drugs not assigned an ATC code.
Vinony links it to 9 Wikipedia language editions.
Chemical data
- Formula
- C19H23N3O3
- Molecular weight
- 341.4 g/mol
- IUPAC name
- N-(2,3-dimethyl-5,6,7,8-tetrahydrofuro[2,3-b]quinolin-4-yl)-2-(2-oxopyrrolidin-1-yl)acetamide
- SMILES
- CC1=C(OC2=NC3=C(CCCC3)C(=C12)NC(=O)CN4CCCC4=O)C
- InChIKey
- PSPGQHXMUKWNDI-UHFFFAOYSA-N
- XLogP
- 2.4
- Polar surface area
- 75.4 Ų
- H-bond donors
- 1
- H-bond acceptors
- 4
- Formal charge
- 0
via PubChem
Drug data · ChEMBL
- Max clinical phase
- Phase 2
- Molecule type
- Small molecule
via ChEMBL · EBI
Wikidata facts
- Subclass of
- chemical compound
- Mass
- 341.174
Show 2 more facts
- chemical formula
- C₁₉H₂₃N₃O₃
- canonical SMILES
- CC1=C(OC2=NC3=C(CCCC3)C(=C12)NC(=O)CN4CCCC4=O)C
Sources (2)
via Wikidata · CC0
~3 min read
Encyclopedic overview
7 sectionsContents
- Pharmacology
- Mechanism of action
- Society and culture
- Legal status
- Australia
- See also
- References
Coluracetam (INN; development code BCI-540; formerly MKC-231) is a purported nootropic agent of the racetam family. It contains a chemical group that is a bioisostere of the 9-amino-tetrahydroacridine family. It was initially developed and tested by the Mitsubishi Tanabe Pharma Corporation for Alzheimer's disease. After the drug failed to reach endpoints in its clinical trials it was in-licensed by BrainCells Inc for investigations into major depressive disorder (MDD), which was preceded by being awarded a "Qualifying Therapeutic Discovery Program Grant" by the state of California. Findings from phase IIa clinical trials have suggested that it would be a potential medication for comorbid MDD with generalized anxiety disorder (GAD). BrainCells Inc is currently out-licensing the drug for this purpose. It may also have potential use in prevention and treatment of ischemic retinopathy and retinal and optic nerve injury.
Coluracetam has been shown to reverse the loss of choline acetyltransferase production in the medial septal nucleus of rats exposed to phencyclidine (PCP), and is considered a potential therapeutic drug for schizophrenia.
Excerpted from Wikipedia’s “coluracetam” article, available under the CC BY-SA 4.0 licence.
Available in 9 languages
via Wikidata sitelinks · CC0